Healthcare

Shingles Vaccine Market Size to Reach USD 20.57 Bn by 2034

Posted on by Priyanka Bhonde
The global shingles vaccine market size was estimated at USD 4.94 billion in 2024 and is expected to hit around USD 20.57 billion by 2034, with a CAGR of 15.34%.
Shingles Vaccine Market Size 2024 to 2034
  • North America dominated the global market with the largest market share of 63% in 2023.
  • Asia Pacific is projected to grow at the fastest CAGR of 16.33% from 202 to 2034.
  • By product, the Shingrix segment contributed the highest market share of 94% in 2023.
  • By product, the SKYZoster segment is expected to grow at the fastest CAGR during the forecast period.
  • By vaccine type, the recombinant vaccine segment captured the biggest market share of 94% in 2023.
  • By vaccine type, the live attenuated vaccine segment shows notable growth during the forecast period.

Shingles Vaccine Market Overview

Shingles is an infectious disease that results in a painful rash, typically appearing on either the left or right side of the torso. It is caused by the varicella-zoster virus, the same virus responsible for chickenpox.

After a person recovers from chickenpox, the virus remains dormant in the body and can reactivate years later, leading to shingles. The condition is widespread globally and is particularly prevalent in densely populated and developing countries such as India and China. It most commonly affects individuals aged 50 and older.

Shingles Vaccine Market Drivers

Growing investments in vaccine research, spurred by the success of recent global immunization efforts, have revitalized interest in developing more effective shingles vaccines. The need for safer alternatives for high-risk groups such as cancer patients and transplant recipients has fueled R&D initiatives. Additionally, the potential for combination vaccines that protect against multiple diseases with a single shot presents a lucrative area for innovation.

Shingles Vaccine Market Opportunities

There are vast opportunities for companies developing thermostable vaccines that do not require refrigeration, thus broadening access in resource-constrained settings. The market also offers potential for mRNA-based shingles vaccines, following the successful application of this technology in COVID-19 vaccines. Partnerships with academic institutions, biotech startups, and global health organizations can accelerate development and expand market reach upon approval.

Increasing demand for Shingrix 

Due to the incredible efficiency of Shingrix vaccines and their fewer side effects, these vaccines covered a major portion of the shingles vaccine market. Also, there is a surge in demand for shingrix vaccines in developed countries such as the U.S. and Canada propelling the market growth soon. Furthermore, the wide adoption of Shingrix has grown because of ongoing launches and approvals of this vaccine in many regions.

  • In September 2024, GlaxoSmithKline Pharmaceutical Sdn Bhd (GSK) announced the launch of its Herpes Zoster vaccine, Shingrix, also called Recombinant Zoster Vaccine, Adjuvanted (RZV) in Malaysia for the prevention of shingles and post-herpetic neuralgia (PHN) in adults aged 50 years and over. RZV is a non-live, recombinant subunit adjuvanted vaccine given intramuscularly in two doses.
  • In May 2024, GSK Egypt announced the launch of the “Shingrix” vaccine to prevent shingles. This announcement was made at a big scientific event attended by a large number of doctors and healthcare professionals from various medical sectors in Egypt and worldwide.

Shingles Vaccine Market Challenges

The pipeline segment faces challenges related to high R&D costs, lengthy regulatory approval processes, and the need for extensive clinical trials to establish safety and efficacy. Market entry is also difficult due to the strong brand presence of existing vaccines like Shingrix. Furthermore, manufacturers must overcome skepticism among healthcare providers and patients when introducing new vaccine technologies, especially in conservative or risk-averse regions.

Shingles Vaccine Market Regional Insights

Research activities are largely concentrated in the United States, Europe, and East Asia, where funding and infrastructure support innovation. Institutions in the U.S. and Germany are leading several clinical trials, while biotech firms in South Korea and China are exploring novel vaccine platforms.

However, the eventual success of these vaccines will depend on global regulatory harmonization, manufacturing scalability, and strategic pricing to ensure equitable access.

Shingles Vaccine Market Recent Developments

  • In April 2024, GSK unveiled results from the ZOSTER-049 trial, which showed that Shingrix effectively protected adults aged 50 and over against shingles for a period of over 10 years.
  • In February 2023, Pfizer Inc and BioNTech SE initiated a phase 1/2 trial exploring the safety, tolerability, and immunogenicity of the companies’ mRNA vaccine candidates against shingles, a debilitating disease caused by the varicella-zoster virus (VZV).
  • In January 2022, BioNTech and Pfizer entered into their third partnership Pfizer providing a sum of USD 225 million. This joint effort aims to utilize RNA technology in the development of a vaccine for shingles.

Shingles Vaccine Market Companies

Segments Covered in the Report

By Product

  • Shingrix
  • Zostavax
  • SkyZoster

By Vaccine Type

  • Recombinant Vaccine
  • Live attenuated Vaccine

By Geography

  • North America
  • Asia Pacific
  • Europe
  • Latin America
  • Middle East and Africa

Ready for more? Dive into the full experience on our website!

https://www.precedenceresearch.com/